UCB has agreed to acquire Zogenix, a biopharmaceutical company focused on rare diseases, for approximately $1.9 billion. The transaction, announced Jan. 19, is expected to close in the second quarter of 2022. General counsel for UCB Bill Silbey and vice president of legal affairs Paul Thompson led the legal team. UCB, which is based in Brussels, was also advised by a Covington & Burling team that included partners J.D. Weinberg, Kyle Rabe and special counsel Gustavo Akkerman. Emeryville, California-based Zogenix was represented by a Latham & Watkins team led by partners Scott Shean, Cheston Larson and Matthew Bush.
Biotech & Pharmaceuticals
January 19, 2022, 10:48 AM